Tadalafil Treatment in Patients With Cerebral Small Vessel Disease: The ETLAS-2 Randomized Clinical Trial
Stroke · 2025-10 · 56 (10) · 2846-2857
DOI: 10.1161/strokeaha.125.051602 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Stroke, 2025-10. Verfasst von Joakim Ölmestig und 12 weiteren Autor:innen. Beteiligte Einrichtung: Neurovascular Research Unit, Department of Neurology (J.O., M.B.T., C.K.), Copenhagen University Hospital-Herlev and Gentofte, Denmark. Hauptthemen laut MEDLINE: Tadalafil, Cerebral Small Vessel Diseases. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: White matter hyperintensities and reduced cerebral blood flow are hallmarks of cerebral small vessel disease (CSVD). We tested the feasibility of daily treatment with the vasoactive drug tadalafil in patients with CSVD and its effects on cognition and imaging markers of CSVD. METHODS: The ETLAS-2 trial (Effect of Tadalafil in Lacunar Stroke) was a randomized, placebo-controlled, double-blind, parallel phase II trial testing 3 months of daily tadalafil 20 mg versus placebo in patients with CSVD and previous stroke or transient ischemic attack. Participants were included from the Capital Region of Denmark from 2022 to 2024. Outcomes were assessed at baseline and after 3 months. A binary logistic regression model with the treatment group as a covariate was used to calculate the primary outcome of feasibility (≥90% study drug compliance). Secondary outcomes included the Montreal Cognitive Assessment, magnetic resonance imaging markers of CSVD (Standards for Reporting Vascular Changes on Neuroimaging criteria), blood pressure, and adverse events. RESULTS: We included 76 participants (20 female, mean age, 68.0±8.9 years). Seventy-one initiated treatment, and 26 of 38 participants with tadalafil were ≥90% compliant versus 31 of 33 with placebo (odds ratio, 0.13 [95% CI, 0.03–0.69]; P =0.030). There was a female preponderance in tadalafil dropouts, with 46% of females stopping treatment, compared with only 16% of males. Adverse events occurred in 76% of participants with tadalafil versus 36% with placebo (odds ratio, 5.49 [95% CI, 1.81–18.07]; P =0.001). A trend toward lower white matter hyperintensity volume at follow-up was observed in the tadalafil group in the unadjusted per-protocol analysis (relative change, 0.939 [95% CI, 0.881–1.001]; P =0.054). No differences were observed in cognition, mental well-being, or blood pressure. CONCLUSIONS: In participants with CSVD, adherence to tadalafil was significantly lower than to placebo and did not meet the prespecified compliance threshold. We observed a nonsignificant reduction in white matter hyperintensity volume after tadalafil, which warrants larger and prolonged studies with reduced tadalafil doses to explore potential benefits in CSVD. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05173896.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neurovascular Research Unit, Department of Neurology (J.O., M.B.T., C.K.), Copenhagen University Hospital-Herlev and Gentofte, Denmark.
- Department of Clinical Medicine (J.O., H.C., H.K.I., H.R.S., C.K.), University of Copenhagen, Denmark.
- Danish Research Centre for Magnetic Resonance, Department of Radiology and Nuclear Medicine, Copenhagen University Hospital-Amager and Hvidovre, Denmark (J.O., K.N.M., H.R.S.).
- Department of Psychology (B.F.), University of Copenhagen, Denmark.
- Child and Adolescent Mental Health Center, Copenhagen University Hospital, Mental Health Services CPH, Hellerup, Denmark (B.F.).
- Department of Radiology (N.N., M.M.N.), Copenhagen University Hospital-Herlev and Gentofte, Denmark.
ORCID-Profile: Joakim Ölmestig, Kristian Nygaard Mortensen, Birgitte Fagerlund, Mette Maria Nordling, Marie Katrine Klose Nielsen, Brian Schou Rasmussen, Hanne Christensen, Helle Klingenberg Iversen, Christina Kruuse
Zitieren
APA
Ölmestig, J., Mortensen, K. N., Thomas, M. B., Fagerlund, B., Naveed, N., Nordling, M. M., Nielsen, M. K. K., Rasmussen, B. S., Christensen, H., Iversen, H. K., Poulsen, M. B., Siebner, H. R., & Kruuse, C. (2025). Tadalafil Treatment in Patients With Cerebral Small Vessel Disease: The ETLAS-2 Randomized Clinical Trial. Stroke, 56(10), 2846-2857. https://doi.org/10.1161/strokeaha.125.051602
Vancouver
Ölmestig J, Mortensen KN, Thomas MB, Fagerlund B, Naveed N, Nordling MM, et al. Tadalafil Treatment in Patients With Cerebral Small Vessel Disease: The ETLAS-2 Randomized Clinical Trial. Stroke. 2025;56(10):2846-2857. doi:10.1161/strokeaha.125.051602
BibTeX
@article{lmestig2025,
author = {Ölmestig, Joakim and Mortensen, Kristian Nygaard and Thomas, Marie Bjerregaard and Fagerlund, Birgitte and Naveed, Nadia and Nordling, Mette Maria and Nielsen, Marie Katrine Klose and Rasmussen, Brian Schou and Christensen, Hanne and Iversen, Helle Klingenberg and Poulsen, Mai Bang and Siebner, Hartwig Roman and Kruuse, Christina},
title = {Tadalafil Treatment in Patients With Cerebral Small Vessel Disease: The ETLAS-2 Randomized Clinical Trial},
journal = {Stroke},
year = {2025},
volume = {56},
number = {10},
pages = {2846--2857},
doi = {10.1161/strokeaha.125.051602}
}
EUVIMED